Victor Jimenez-Yuste
Overview
Explore the profile of Victor Jimenez-Yuste including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
170
Citations
2169
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Raventos A, Arias-Salgado E, Perez A, Alvarez-Roman M, Butta N, Monzon Manzano E, et al.
Clin Exp Med
. 2024 Dec;
25(1):14.
PMID: 39708197
Hemophilia A (HA) patients under emicizumab prophylaxis may require the concomitant use of procoagulant factors for breakthrough bleedings or immune tolerance induction (ITI). The aim of this study is to...
2.
Tyrrell P, Alvarez-Roman M, Bakeer N, Brand-Staufer B, Jimenez-Yuste V, Kras S, et al.
Res Pract Thromb Haemost
. 2024 Dec;
8(8):102602.
PMID: 39677374
Background: Recurrent hemarthrosis and resultant hemophilic arthropathy are significant causes of morbidity in persons with hemophilia, despite the marked evolution of hemophilia care. Prevention, timely diagnosis, and treatment of bleeding...
3.
Dunn A, Dargaud Y, Abajas Y, Carcao M, Castaman G, Giermasz A, et al.
Haemophilia
. 2024 Dec;
31(1):78-86.
PMID: 39676340
Introduction: Eptacog beta is a novel human recombinant FVIIa approved for use in the United States, European Union, United Kingdom and Mexico for the treatment and control of bleeding in...
4.
Skinner M, Albisetti M, Ardila J, Astermark J, Blatny J, Carcao M, et al.
Haemophilia
. 2024 Dec;
PMID: 39648854
Introduction: The 2024 ISTH clinical practice guideline (CPG) for treatment of congenital haemophilia, the NBDF-McMaster Guideline on Care Models for Haemophilia Management, and ASH ISTH NBDF WFH guidelines on the...
5.
Albisetti M, Ardila J, Astermark J, Blatny J, Carcao M, Chowdary P, et al.
Haemophilia
. 2024 Dec;
PMID: 39642092
Introduction: Evidence-based clinical practice guidelines drive optimal patient care and facilitate access to high-quality treatment. Creating guidelines for rare diseases such as haemophilia, where evidence does not often come from...
6.
Jimenez-Yuste V
Semin Thromb Hemost
. 2024 Nov;
51(1):23-27.
PMID: 39613145
Non-factor replacement therapies (NFTs) have been developed to address the limitations of conventional replacement therapies, aiming to improve hemostasis and provide enhanced protection against bleeding episodes and long-term joint damage...
7.
Blatny J, Astermark J, Catarino C, Dolan G, Fijnvandraat K, Hermans C, et al.
Ther Adv Hematol
. 2024 Oct;
15:20406207241285143.
PMID: 39381602
Over recent decades, management of people with hemophilia (PwH) has been greatly improved by scientific advances that have resulted in a rich and varied therapeutic landscape. Nevertheless, treatment limitations continue...
8.
Konigs C, Motwani J, Jimenez-Yuste V, Blatny J
J Clin Med
. 2024 Sep;
13(17).
PMID: 39274334
Adolescents with hemophilia are a patient population with special requirements, having to manage their condition alongside the typical challenges of adolescence. Given the psychosocial impact of hemophilia and a desire...
9.
De la Corte-Rodriguez H, Rodriguez-Merchan E, Alvarez-Roman M, Gomez-Cardero P, Jimenez-Yuste V
Expert Rev Hematol
. 2024 Jul;
17(8):419-430.
PMID: 39008070
Introduction: The therapeutic approach to pain in hemophilia should be multimodal. Intra-articular injections are a good option when joint lesions do not respond to hematological treatment or rehabilitation and orthopedic...
10.
Jimenez-Yuste V, Oldenburg J, Tzeng E, Lim E, Sanabria F, Mahlangu J
Res Pract Thromb Haemost
. 2024 May;
8(3):102405.
PMID: 38783987
Background: The treatment of older people with hemophilia A (HA) can be complicated by comorbidities. Objectives: This post hoc analysis evaluates the efficacy and safety of emicizumab in people with...